Anna Orlova
Tomsk Polytechnic University
BiophysicsMolecular imagingPathologyMolecular biologyReceptorChemistryConjugateIn vitroIn vivoBiodistributionDOTAProstate cancerAffibody moleculeNuclear medicineRadionuclide therapyMoleculeCancer researchMonoclonal antibodyBiochemistryMedicine
324Publications
53H-index
6,431Citations
Publications 288
Newest
Source
#1O. D. Bragina (RAS: Russian Academy of Sciences)H-Index: 1
#2V. I. Chernov (RAS: Russian Academy of Sciences)H-Index: 3
Last. V. M. Tolmachev (Tomsk Polytechnic University)H-Index: 1
view all 7 authors...
Source
#1Olga Bragina (RAS: Russian Academy of Sciences)H-Index: 4
#2Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
Last. Vladimir Tolmachev (Uppsala University)H-Index: 60
view all 16 authors...
Radionuclide molecular imaging of human epidermal growth factor (HER2) expression may be helpful to stratify breast and gastroesophageal cancer patients for HER2-targeting therapies. ADAPTs (albumin-binding domain derived affinity proteins) are a new type of small (46-59 amino acids) proteins useful as probes for molecular imaging. The aim of this first-in-human study was to evaluate biodistribution, dosimetry, and safety of the HER2-specific 99mTc-ADAPT6. METHODS: Twenty-nine patients with prim...
7 CitationsSource
#1Sara S. RinneH-Index: 8
#2Anna Orlova (Tomsk Polytechnic University)H-Index: 53
Last. Vladimir TolmachevH-Index: 60
view all 3 authors...
The human epidermal growth factor receptor family (EGFR-family, other designations: HER family, RTK Class I) is strongly linked to oncogenic transformation. Its members are frequently overexpressed in cancer and have become attractive targets for cancer therapy. To ensure effective patient care, potential responders to HER-targeted therapy need to be identified. Radionuclide molecular imaging can be a key asset for the detection of overexpression of EGFR-family members. It meets the need for rep...
Source
#1Haozhong DingH-Index: 3
#2Tianqi XuH-Index: 2
Last. Anzhelika VorobyevaH-Index: 10
view all 8 authors...
Affibody molecules hold great promise as carriers of cytotoxic drugs for cancer therapy due to their typically high affinity, easy production, and inherent control of the drug molecules' loading and spatial arrangement. Here, the impact of increasing the drug load from one to three on the properties of an affibody drug conjugate targeting the human epidermal growth factor receptor 2 (HER2) was investigated. The affibody carrier was recombinantly expressed as a fusion to an albumin-binding domain...
Source
#1Maryam Oroujeni (Uppsala University)H-Index: 7
#2Sara S. Rinne (Uppsala University)H-Index: 8
Last. Vladimir TolmachevH-Index: 60
view all 10 authors...
Radionuclide imaging of HER2 expression in tumours may enable stratification of patients with breast, ovarian, and gastroesophageal cancers for HER2-targeting therapies. A first-generation HER2-binding affibody molecule [99mTc]Tc-ZHER2:V2 demonstrated favorable imaging properties in preclinical studies. Thereafter, the affibody scaffold has been extensively modified, which increased its melting point, improved storage stability, and increased hydrophilicity of the surface. In this study, a secon...
Source
#1Maryam OroujeniH-Index: 7
#2Tianqi XuH-Index: 2
Last. Vladimir TolmachevH-Index: 60
view all 10 authors...
Epidermal growth factor receptor (EGFR) is overexpressed in many malignancies. EGFR-targeted therapy extends survival of patients with disseminated cancers. Radionuclide molecular imaging of EGFR expression would make EGFR-directed treatment more personalized and therefore more efficient. A previous study demonstrated that affibody molecule [68Ga]Ga-DFO-ZEGFR:2377 permits specific positron-emission tomography (PET) imaging of EGFR expression in xenografts at 3 h after injection. We anticipated t...
1 CitationsSource
#1Sara S. Rinne (Uppsala University)H-Index: 8
#2Ayman Abouzayed (Uppsala University)H-Index: 4
Last. Anna Orlova (Tomsk Polytechnic University)H-Index: 53
view all 5 authors...
Molecular imaging of the gastrin-releasing peptide receptor (GRPR) could improve patient management in prostate cancer. This study aimed to produce gallium-66 (T½ = 9.5 h) suitable for radiolabeling, and investigate the imaging properties of gallium-66 labeled GRPR-antagonist NOTA-PEG2-RM26 for later-time point PET-imaging of GRPR expression. Gallium-66 was cyclotron-produced using a liquid target, and enriched [66Zn]Zn(NO3)2. In vitro, [66Ga]Ga-NOTA-PEG2-RM26 was characterized in GRPR-expressin...
1 CitationsSource
#1Ayman Abouzayed (Uppsala University)H-Index: 4
#2Sara S. Rinne (Uppsala University)H-Index: 8
Last. Anna Orlova (Uppsala University)H-Index: 53
view all 7 authors...
Background: Gastrin-releasing peptide receptor (GRPR) is an important target for imaging of prostate cancer. The wide availability of single-photon emission computed tomography/computed tomography (SPECT/CT) and the generator-produced 99mTc can be utilized to facilitate the use of GRPR-targeting radiotracers for diagnostics of prostate cancers. Methods: Synthetically produced mercaptoacetyl-Ser-Ser-Ser (maSSS)-PEG2-RM26 and mercaptoacetyl-Ser-Glu-Ser (maSES)-PEG2-RM26 (RM26 = d-Phe-Gln-Trp-Ala-V...
Source
#1Hanna TanoH-Index: 1
#2Maryam OroujeniH-Index: 7
Last. Vladimir TolmachevH-Index: 60
view all 10 authors...
Affibody-mediated PNA-based pretargeting is a promising approach to radionuclide therapy of HER2-expressing tumors. In this study, we test the hypothesis that shortening the PNA pretargeting probes would increase the tumor-to-kidney dose ratio. The primary probe ZHER2:342-SR-HP15 and the complementary secondary probes HP16, HP17, and HP18, containing 9, 12, and 15 nucleobases, respectively, and carrying a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator were designed, syn...
Source